TGTX
USDTG Therapeutics Inc. Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$33.070
Haut
$34.325
Bas
$32.772
Volume
1.47M
Fondamentaux de l'Entreprise
Capitalisation Boursière
5.4B
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
2.11M
Bourse
NCM
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $49
JP Morgan analyst Eric Joseph maintains TG Therapeutics with a Overweight and raises the price target from $46 to $49.
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI U.S. net revenue target
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.